Pyxis Oncology (PYXS) – Investment Analysts’ Recent Ratings Changes

Pyxis Oncology (NASDAQ: PYXS) recently received a number of ratings updates from brokerages and research firms:

• 3/24/2026 – Pyxis Oncology had its price target lowered by Stifel Nicolaus from $9.00 to $8.00. They now have a “buy” rating on the stock.
• 3/24/2026 – Pyxis Oncology had its “buy” rating reaffirmed by HC Wainwright. They now have a $7.00 price target on the stock.
• 3/15/2026 – Pyxis Oncology was downgraded by Wall Street Zen from “hold” to “sell”.
• 3/7/2026 – Pyxis Oncology was upgraded by Wall Street Zen from “sell” to “hold”.
• 1/25/2026 – Pyxis Oncology was downgraded by Wall Street Zen from “hold” to “sell”.

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.